This study is accepting new patients by invitation only

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

a study on Peanut Allergy

Summary

Eligibility
for people ages 2-5 (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around

Description

Summary

Open-label, follow-up study for subjects who completed the EPITOPE study.

Official Title

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Keywords

Peanut Allergy, EPIT, Epicutaneous, Immunotherapy, Viaskin, Peanut Hypersensitivity, DBV712 250 mcg, DBV712 250mcg

Eligibility

You can join if…

Open to people ages 2-5

  • completion of the EPITOPE study

You CAN'T join if...

  • Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.
  • Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma

Locations

  • David Geffen School of Medicine at University of California Los Angeles
    Los Angeles California 90095 United States
  • University of California San Francisco
    San Francisco California 94158 United States
  • Rady Children's Hospital San Diego
    San Diego California 92123 United States
  • Stanford University School of Medicine
    Stanford California 94305 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
DBV Technologies
ID
NCT03859700
Phase
Phase 3 Peanut Allergy Research Study
Study Type
Interventional
Participants
Expecting 330 study participants
Last Updated